Table 2.
Development of inflammation and disease activity in cases, controls and the remainder of the RABBIT cohort stratified by enrolment therapy
| Treatment at baseline | Number | Mean at baseline (95 % CI) | Mean at month 3 (95 % CI) | Mean at month 6 (95 % CI) | |
|---|---|---|---|---|---|
| CRP (mg/L) | |||||
| Cases | csDMARD | 37 | 21.6 (12.4; 30.8) | 16.3 (9.0; 23.6) | 14.3 (7.3; 21.2) |
| bDMARD | 75 | 24.4 (18.2; 30.6) | 19.5 (14.5; 24.5) | 19.4 (13.5; 25.4) | |
| Controls | csDMARD | 40 | 10.2 (6.1; 14.3) | 9.8 (5.1; 14.5) | 8.0 (4.7; 11.3) |
| bDMARD | 72 | 20.0 (14.1; 25.9) | 11.4 (7.4; 15.4) | 11.0 (6.9; 15.0) | |
| Cohort remainder | csDMARD | 3656 | 14.1 (13.5; 14.8) | 11.4 (10.8; 11.9) | 11.0 (10.4; 11.5) |
| bDMARD | 7403 | 20.75 (20.1; 21.4) | 12.9 (12.4; 13.3) | 12.7 (12.2; 13.1) | |
| ESR (mm/h) | |||||
| Cases | csDMARD | 37 | 30.4 (23.9; 36.9) | 27.7 (20.9; 34.5) | 31.4 (23.8; 39.0) |
| bDMARD | 75 | 43.2 (35.9; 50.4) | 36.8 (30.5; 43.2) | 34.7 (28.7; 40.7) | |
| Controls | csDMARD | 40 | 26.8 (20.2; 33.4) | 22.4 (16.5; 28.2) | 19.4 (13.1; 25.7) |
| bDMARD | 72 | 32.8 (28.1; 37.5) | 22.7 (18.4; 27.1) | 22.6 (18.8; 26.4) | |
| Cohort remainder | csDMARD | 3656 | 27.4 (26.7; 28.0) | 23.9 (23.3; 24.5) | 23.5 (22.8; 24.2) |
| bDMARD | 7403 | 33.3 (32.7; 33.8) | 24.4 (24.0; 24.9) | 24.4 (24.0; 25.0) | |
| DAS28 | |||||
| Cases | csDMARD | 37 | 5.2 (4.8; 5.5) | 4.0 (3.5; 4.4) | 3.9 (3.4; 4.3) |
| bDMARD | 75 | 5.8 (5.5; 6.1) | 4.6 (4.2; 5.0) | 4.6 (4.2; 5.0) | |
| Controls | csDMARD | 40 | 4.8 (4.4; 5.3) | 4.0 (3.6; 4.5) | 3.5 (3.0; 4.0) |
| bDMARD | 72 | 5.9 (5.6; 6.1) | 4.1 (3.7; 4.4) | 3.9 (3.6; 4.3) | |
| Cohort remainder | csDMARD | 3656 | 4.8 (4.7; 4.8) | 3.8 (3.7; 3.8) | 3.7 (3.6; 3.7) |
| bDMARD | 7403 | 5.4 (5.4; 5.5) | 4.0 (3.9; 4.0) | 3.9 (3.8; 3.9) | |
Mean values are averaged over five imputations and CI were corrected for the imputation variance
CI confidence interval, CRP C-reactive protein, ESR erythrocyte sedimentation rate, DAS28 disease activity score based on 28 joints, bDMARD biologic disease-modifying antirheumatic drug, csDMARD conventional synthetic DMARD